PharmaCyte BiotechPMCB -0.50%30 Return-on-Tangible-Asset is 5.50% as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, PharmaCyte Biotech ranks better than 74.17% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. PharmaCyte Biotech's annualizedNet Income for the quarter that ended in Jan. 2026 was $2.99 Mil. PharmaCyte Biotech's average total tangible assets for the quarter that ended in Jan. 2026 was $54.38 Mil. Therefore, PharmaCyte Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2026 was 5.50%.
The historical rank and industry rank for PharmaCyte Biotech's Return-on-Tangible-Asset or its related term are showing as below:
PMCB'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -171.11 Med: -105.77 Max: 54.76
Current: -6.61
During the past 13 years, PharmaCyte Biotech's highest Return-on-Tangible-Asset was 54.76%. The lowest was -171.11%. And the median was -105.77%.
PMCB's Return-on-Tangible-Asset is ranked better than 74.17% of 1413
companies
in the Biotechnology industry
Industry Median: -35.77
vs PMCB: -6.61
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
PharmaCyte Biotech Return-on-Tangible-Asset Related Terms
PharmaCyte Biotech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMCB vs ERNA, SYBX, ASBP: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, PharmaCyte Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jan. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.50% mean?
PharmaCyte Biotech (PMCB) has a Return-on-Tangible-Asset of 5.50% as of Jan. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #365 out of 1413 companies in the Biotechnology industry, placing it in the top 25.8%.
Is PharmaCyte Biotech's Return-on-Tangible-Asset too high?
PharmaCyte Biotech's current Return-on-Tangible-Asset is 5.50%. Based on the distribution chart, PharmaCyte Biotech ranks #365 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PharmaCyte Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Return-on-Tangible-Asset compare to ERNA and SYBX?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #365 out of 1413 companies for Return-on-Tangible-Asset. This puts PharmaCyte Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Return-on-Tangible-Asset is 5.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Return-on-Tangible-Asset of 5.50%. The current Return-on-Tangible-Asset is 5.50%. PharmaCyte Biotech's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Return-on-Tangible-Asset is 5.50% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
30GF Score
Get the complete analysis for PMCB
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
